| 141 | 8 | 170 |
| 下载次数 | 被引频次 | 阅读次数 |
目的观察甲钴胺联合α-硫辛酸治疗对糖尿病神经病变(DN)患者神经症状的改变及对血清氧化应激水平的影响。方法选取DN患者58例,随机分为观察组33例和对照组25例。对照组予甲钴胺(1 mg·d-1, iv)治疗,观察组予甲钴胺联合α-硫辛酸(甲钴胺1 mg·d-1+α-硫辛酸600 mg·d-1,iv)治疗,疗程均为10d。记录2组患者治疗前后的DN症状学评分,并检测治疗前后血清半胱氨酸蛋白酶抑制剂C(CysC)、8-羟基脱氧鸟苷(8-OHd G)、白介素-6(IL-6)、同型半胱氨酸(Hcy)和可溶性细胞黏附分子-1(s ICAM-1)水平。结果治疗后,观察组DN症状学评分不仅低于同组治疗前(P <0.05),也低于对照组(P <0.05);而对照组DN症状学评分虽较同组治疗前有所降低,但差异未见统计学意义(P> 0.05)。治疗前后,2组CysC、8-OHd G、IL-6、Hcy和s ICAM-1水平经比较,组间差异均无统计学意义(P> 0.05)。与治疗前相比,观察组治疗后血清CysC水平显著降低(P <0.05),余指标差异均无统计学意义(P> 0.05)。结论与单药甲钴胺相比,甲钴胺联合α-硫辛酸治疗可降低DN患者DN症状学评分,提示对患者的临床神经症状有改善作用;同时可降低血清CysC水平,提示血清CysC对DN患者的临床预后可能有预测价值。
Abstract：AIM To observe the effect of mecobalamin combined with α-lipoic acid on the changes of neurological symptoms and serum oxidative stress level in patients with diabetic neuropathy(DN). METHODS A total of 58 patients with DN were randomly divided into observation group(n=33) and control group(n=25). The patients in control group were treated with mecobalamin(1 mg·d-1, iv), while the patients in observation group were treated with mecobalamin(1 mg·d-1, iv) combined with α-lipoic acid(600 mg·d-1, iv). All patients were treated for 10 d. The DN symptom scores of 2 groups before and after treatment were recorded, and the serum cystatin C(CysC), 8-hydroxy-2'-deoxyguanosine(8-OHdG), interleukin-6(IL-6), homocysteine(Hcy) and soluble intercellular adhesion molecule-1(sICAM-1) levels were detected before and after treatment. RESULTS After treatment, the DN symptom scores in the observation group were not only lower than those before treatment(P < 0.05), but also lower than those in the control group(P < 0.05); the DN symptom scores in the control group were lower than those before treatment, but the difference was not statistically significant(P > 0.05). Before and after treatment, there was no significant difference in the levels of CysC, 8-OHdG, IL-6, Hcy and sICAM-1 between 2 groups(P > 0.05). Compared with before treatment, the level of serum CysC in the observation group was decreased significantly after treatment(P < 0.05), and there was no significant difference in other indexes(P > 0.05). CONCLUSION Compared with mecobalamin monotherapy, mecobalamin combined α-lipoic acid treatment can reduce the DN symptom scores of patients with DN, suggesting that it can improve the clinical neurological symptoms of patients; it can reduce the level of serum CysC at the same time, suggesting that serum CysC may have predictive value for the clinical prognosis of patients with DN.
[1]DIXIT S,MAIYA A,SHASTRY B.Effect of aerobic exercise on quality of life in population with diabetic peripheral neuropathy in type2 diabetes:a single blind,randomized controlled trial[J].Qual Life Res,2014,23(5):1629.
[2]HICKS C W,SELVIN E.Epidemiology of peripheral neuropathy and lower extremity disease in diabetes[J].Curr Diab Rep,2019,19(10):86.
[3]CHICHARRO-LUNA E,POMARES-GOMEZ F J, ORTEGA-AVILA A B,et al.Variability in the clinical diagnosis of diabetic peripheral neuropathy[J].Prim Care Diabetes,2020,14(1):53.
[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315.
[5] TANG H Y,JIANG A J,MA J L,et al.Understanding the signaling pathways related to the mechanism and treatment of diabetic peripheral neuropathy[J].Endocrinology,2019,160(9):2119.
[6]DYCK P J.Detection,characterization,and staging of polyneuropathy:assessed in diabetics[J].Muscle Nerve,1988,11(1):21.
[7]MEIJER J W G,SMIT A J,SONDEREN E V,et al.Symptom scoring systems to diagnose distal polyneuropathy in diabetes:the Diabetic Neuropathy Symptom score[J].Diabet Med,2002,19(11):962.
[8]JAYAPRAKASH P,BHANSALI A,BHANSALI S, et al.Validation of bedside methods in evaluation of diabetic peripheral neuropathy[J].Indian J Med Res,2011,133:645.
[9]ASMAT U, ABAD K, ISMAIL K.Diabetes mellitus and oxidative stress-A concise review[J].Saudi Pharm J,2016,24(5):547.
[10]HALIM M,HALIM A.The effects of inflammation,aging and oxidative stress on the pathogenesis of diabetes mellitus(type 2diabetes)[J].Diabetes Metab Syndr,2019,13(2):1165.
[11]PANG L,LIAN X,LIU H Q,et al.Understanding diabetic neuropathy:focus on oxidative stress[J].Oxidative Med Cell Longev,2020,2020:9524635.
[12]VOLPE C M O, VILLAR-DELFINO P H, DOS ANJOS P M F,et al.Cellular death, reactive oxygen species(ROS)and diabetic complications[J].Cell Death Dis,2018,9(2):119.
[13]GALLOWAY C, CHATTOPADHYAY M.RETRACTED:Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in Type 2 diabetes[J].Cytokine,2013,63(1):1.
[14]GARCIA-ALCALA H, SANTOS VICHIDO C I,ISLAS MACEDO S,et al.Treatment with a-lipoic acid over 16 weeks in type 2 diabetic patients with symptomatic polyneuropathy who responded to initial4-week high-dose loading[J].J Diabetes Res,2015,2015:189857.
[15]ZIEGLER D, LOW P A,FREEMAN R, et al.Predictors of improvement and progression of diabetic polyneuropathy following treatment with a-lipoic acid for 4 years in the NATHAN 1 trial[J].J Diabetes Complications,2016,30(2):350.
[16]SERDAR M,SERTOGLU E,UYANIK M,et al.Comparison of 8-hydroxy-2'-deoxy guanosine(8-OHdG)levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy[J].Free Radic Res,2012,46(10):1291.
[17]MUZUROVIC E,KRALJEVIC I,SOLAK M,et al.Homocysteine and diabetes:role in macrovascular and microvascular complications[J].J Diabetes Complications,2021,35(3):107834.
[18]KHALILI M,AZIMI A,IZADI V,et al.Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients:a doubleblind,placebo-controlled,randomized clinical trial[J].Neuroimmunomodulation, 2014,21(6):291.
[19]崔娇娇,雷根平,董盛.早期诊断糖尿病肾病生化指标的研究进展[J].中华实用诊断与治疗杂志,2021,35(5):538.
[20]XU L L,GAO W,CHEN Z M,et al.Relationships between diabetic nephropathy and insulin resistance,inflammation,Trx,Txnip,CysC and serum complement levels[J].Eur Rev Med Pharmacol Sci,2020,24(22):11700.
[21]HU Y,LIU F,SHEN J,et al.Association between serum cystatin C and diabetic peripheral neuropathy:a cross-sectional study of a Chinese type 2 diabetic population[J].Eur J Endocrinol,2014,171(5):641.
[22]晏丕军,张志红,徐勇,等.2型糖尿病患者血清胱抑素C水平与振动感觉阈值的关系[J].中南大学学报:医学版,2016,41(1):58.
基本信息:
DOI：10.19577/j.1007-4406.2021.05.002
中图分类号:R587.2
引用信息:
[1]孙华,顾芹,聂晶,等.甲钴胺联合α-硫辛酸治疗糖尿病神经病变的疗效及对血清氧化应激水平的影响[J].中国临床药学杂志,2021,30(05):325-329.DOI:10.19577/j.1007-4406.2021.05.002.
2021-09-25
2021-09-25